My research focuses on the mechanisms by which osteocytes contribute to generate a microenvironment that is conducive to tumor progression, bone destruction and muscle weakness in multiple myeloma disease. Current projects investigate the effects of genetic and pharmacological inhibition of osteocyte-derived factors (i.e Sclerostin, Rankl) in tumor growth and multiple myeloma-induced bone fragility and muscle weakness; the role of bidirectional Notch signaling between MM cells and osteocytes in multiple myeloma disease; and the effects of Aplidin (a novel anti-tumor drug that targets eEF1A2), alone or in combination with other anti-tumor drugs, on bone cells and tumor progression. I also collaborate in studies examining the role of osteocytes in multiple myeloma-induced bone pain; the regulation of the skeletal actions of parathyroid hormone; and the deleterious effects that glucocorticoids have in the skeleton.


My research focuses on understanding the mechanisms by which myeloma cells alter the biology of other cells in the tumor/bone marrow microenvironment with the final goal of identifying targetable factors for the treatment of multiple myeloma.


Oncology, Oncology, Hematology, Human Anatomy, Cell Biology
PhD, University of Cantabria, Bone Epigenetics, 2012
MA, University of Cantabria, Molecular Biology and Biomedicine, 2009
BS, University of the Basque Country, Biochemistry, 2006